IMPAIRED PROLACTIN RESPONSE TO ARGININE IN PATIENTS WITH HYPERTHYROIDISM

被引:2
|
作者
CICCARELLI, E
ZINI, M
GROTTOLI, S
RAZZORE, P
PORTIOLI, I
VALCAVI, R
机构
[1] ARCISPEDALE S MARIA NUOVA,DIV MED INTERNA 2,I-42100 REGGIO EMILIA,ITALY
[2] ARCISPEDALE S MARIA NUOVA,SEZ ENDOCRINO METAB,I-42100 REGGIO EMILIA,ITALY
[3] UNIV TURIN,DIPARTIMENTO FISIOPATOL CLIN,DIV ENDOCRINOL,TURIN,ITALY
关键词
D O I
10.1111/j.1365-2265.1994.tb02559.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Reduced PRL responses to TRH or dopamine antagonists have been described in hyperthyroid patients. Arginine stimulates PRL secretion through pathways other than the activation of TRH receptors or dopamine-dependent mechanisms. We therefore investigated PRL responses to arginine in patients with hyperthyroidism. DESIGN L-Arginine (30 g infused over 30 minutes) was administered at time zero. SUBJECTS Sixteen patients with untreated hyperthyroidism due to Graves' disease (8 female and 8 male), with a mean age (+/- SE) of 31.3 +/- 1.4 years (range 23-42), and 12 normal subjects (6 female and 6 male, ages 30.1 +/- 2.1 years, range 22-47) were studied. MEASUREMENTS Prolactin was measured by RIA between -30 and 120 minutes, at 15-minute intervals. RESULTS Basal PRL levels were similar in the hyperthyroid patients and normal control subjects. The hyperthyroid women showed blunted PRL responses compared to normal women (peak PRL levels, 364 +/- 44 mU/l, vs 760 +/- 156, P < 0.02). PRL responses to arginine, small but clearly detectable in normal men, were completely abolished in hyperthyroid men (peak PRL levels, 248 +/- 48 mU/l, vs 112 +/- 14, P < 0.01). CONCLUSIONS PRL responses to arginine are impaired in hyperthyroid patients. Therefore; arginine should be added to the list of PRL stimuli whose responses are blunted in hyperthyroidism. Inhibition of PRL gene expression, and thus reduced pituitary PRL synthesis
引用
收藏
页码:371 / 374
页数:4
相关论文
共 50 条
  • [1] PROLACTIN RESPONSE TO ARGININE IN NORMAL SUBJECTS AND IN PATIENTS WITH HYPERTHYROIDISM
    ONISHI, T
    ITOH, KF
    MIYAI, K
    IZUMI, K
    SHIMA, K
    KUMAHARA, Y
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1976, 42 (01): : 148 - 151
  • [2] PROLACTIN RESPONSE TO ARGININE IN CHILDREN WITH HYPERTHYROIDISM AND PRIMARY HYPOTHYROIDISM
    ABE, K
    MATSUURA, N
    FUJITA, H
    FUJIEDA, K
    KATO, T
    NOHARA, Y
    MIKAMI, Y
    FUKUSHIMA, N
    EUROPEAN JOURNAL OF PEDIATRICS, 1982, 139 (02) : 118 - 120
  • [3] PROLACTIN RESPONSE TO METOCLOPRAMIDE IN HYPERTHYROIDISM
    SAWERS, JSA
    KELLETT, HA
    BROWN, NS
    SETH, J
    TOFT, AD
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 55 (01): : 175 - 177
  • [4] IMPAIRED PROLACTIN RESPONSE TO ARGININE INFUSION AND INSULIN HYPOGLYCEMIA IN CHRONIC-RENAL-FAILURE
    SCHMITZ, O
    MOLLER, J
    ACTA ENDOCRINOLOGICA, 1983, 102 (04): : 486 - 491
  • [5] STUDY OF THE RESPONSE OF PROLACTIN TO TRH IN PATIENTS WITH HYPERTHYROIDISM IN REMISSION EXHIBITING AN ANOMALY IN THYROTROPIC FUNCTION
    JAFFIOL, C
    ORSETTI, A
    BALDET, L
    PAPACHRISTOU, C
    ANNALES D ENDOCRINOLOGIE, 1982, 43 (02) : 140 - 140
  • [6] PROLACTIN RESPONSE TO CHLORPROMAZINE AND THYROTROPIN-RELEASING-HORMONE IN HYPERTHYROIDISM
    ONISHI, T
    MIYAI, K
    IZUMI, K
    NAKANISHI, H
    KUMAHARA, Y
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1975, 40 (01): : 30 - 32
  • [7] IMPAIRED PROLACTIN SECRETION IN OBESE PATIENTS
    CAVAGNINI, F
    MARASCHINI, C
    PINTO, M
    DUBINI, A
    POLLI, EE
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1981, 4 (02) : 149 - 153
  • [8] Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism
    Kahaly, G
    Hellermann, J
    MohrKahaly, S
    Treese, N
    CHEST, 1996, 109 (01) : 57 - 61
  • [9] INSULIN DELIVERY RATE IN RESPONSE TO GLUCOSE AND ARGININE INFUSION IN HYPERTHYROIDISM
    ASANO, T
    OKUMURA, M
    DIABETOLOGIA, 1982, 23 (02) : 108 - 113
  • [10] Impaired insulin response to arginine in NIDDM patients with secondary failure to sulfonylurea treatment
    Taniguchi, T
    Kuno, S
    Kitada, M
    Seko, S
    Okamoto, M
    DIABETES, 1998, 47 : A345 - A345